Dr. Eric A. Kirk, M.D.
Nephrology (Kidney) (Nephrology Physician)
- Medicare participating
At a glance
- Medical school
- Indiana University School of Medicine (2005)
- Years since graduation
- 21
- In the NPI registry since
- 2007
- Medicare patients seen, 2024
- 604
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2005Medical school: Indiana University School of Medicine
- 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Nephrology Physician primary
NC license 2015-01241 · SC license 32977 -
Internal Medicine Physician
MI license 4301086097 -
Pediatrics Physician
MI license 4301086097
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Novant Health New Hanover Regional Medical Center Wilmington, NC
- Novant Health Brunswick Medical Center Supply, NC
- J Arthur Dosher Memorial Hospital Southport, NC
- Pender Memorial Hospital Burgaw, NC
Medical groups
- Eastern Nephrology Associates PLLC (77 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 604
- Services billed
- 5,757
- Patients’ average age
- 74
| Service | Times | Patients |
|---|---|---|
| Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units | 1,270 | 36 |
| Established patient office or other outpatient visit, 30-39 minutes | 387 | 250 |
| Insertion of needle into vein for collection of blood sample | 379 | 202 |
| Kidney function blood test panel | 349 | 193 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test | 277 | 176 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 261 | 151 |
| Parathormone (parathyroid hormone) level | 249 | 172 |
| Creatinine level to test for kidney function or muscle injury | 240 | 160 |
| Total protein level, urine | 237 | 158 |
| Vitamin d-3 level | 198 | 154 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Furosemide Other prescribers in Wilmington, NC | 179 |
| Losartan Potassium Other prescribers in Wilmington, NC | 130 |
| Jardiance (empagliflozin) Other prescribers in Wilmington, NC | 114 |
| Calcitriol Other prescribers in Wilmington, NC | 92 |
| Amlodipine Besylate Other prescribers in Wilmington, NC | 62 |
| Spironolactone Other prescribers in Wilmington, NC | 53 |
| Farxiga (dapagliflozin propanediol) Other prescribers in Wilmington, NC | 53 |
| Hydralazine Hcl Other prescribers in Wilmington, NC | 52 |
| Lisinopril Other prescribers in Wilmington, NC | 49 |
| Carvedilol Other prescribers in Wilmington, NC | 48 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 8 companies reported 12 payments worth $456 in total to this clinician.
| Nxstage Medical, Inc. | $260 |
|---|---|
| Amgen Inc. | $57.55 |
| Lilly USA, LLC | $31.17 |
| Novartis Pharmaceuticals Corporation | $25.02 |
| Otsuka America Pharmaceutical, Inc. | $24.56 |
| Ani Pharmaceuticals, Inc. | $21.14 |
| Akebia Therapeutics Inc | $18.36 |
| AstraZeneca Pharmaceuticals LP | $18.10 |
| Food and Beverage | $456 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 10 industry-funded studies in 2025, from 5 companies. The companies reported $561,884 in research payments for these studies, mostly to the institutions running them.
- A Phase III, Randomised, Multicentre, Double-blind Study to Evaluate the Efficacy, Safety and Tolerability of Zibotentan/Dapagliflozin FDC Compared to Dapagliflozin Alone in Participants with Chronic Kidney Disease an…
AstraZeneca Pharmaceuticals LP - A phase 3,randomised,double blind,active controlled study to assess the efficacy,safety and tolerability of baxdrostat in combination with dapagliflozin compared with dapagliflozin alone on chronic kidney disease ckd …
AstraZeneca Pharmaceuticals LP - A Phase 2/3 Adaptive, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of VX-147 in Subjects Aged 18 Years and Older With APOL1-mediated Proteinuric Kidney Disease
Vertex Pharmaceuticals Incorporated - Phase 2b Multicentre, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Dose-Ranging Study to Assess the Efficacy, Safety, and Tolerability of AZD2373 in Participants with APOL1-Mediated Kidney Disease (APP…
AstraZeneca UK Limited - A phase III,randomised,double blind,placebo controlled,event driven study to assess the efficacy,safety and tolerability of baxdrostat in combination with dapagliflozin compared with dapagliflozin alone on renal outco…
AstraZeneca Pharmaceuticals LP - A Study of the Prevalance of Apolipoprotein L1 (APOL1) Alleles Among Individuals With Proteinuric Kidney Disease Who Are of Recent African Ancestry or Geographic Origin
Vertex Pharmaceuticals Incorporated - Efficacy and Safety of Volenrelaxin in Adults With Chronic Kidney Disease
Eli Lilly and Company · Withdrawn · NCT06598631 - A Randomised Double-Blind Placebo-Controlled Parallel Group Study to Assess the Effect of Baxdrostat on Ambulatory Blood Pressure in Participants with Resistant Hypertension
AstraZeneca Pharmaceuticals LP - A randomized, double-blind, placebo-controlled, parallel-group, multicenter Phase 3 study to investigate the efficacy and safety of FInerenone, in addition to standard of care, on the progression of kidney disease i…
Bayer HealthCare Pharmaceuticals Inc. - BAY 948862, A randomised, double-blind, placebo-controlled, parallel-group, multicentre Phase 3 study to investigate the efficacy and safety of Finerenone, in addition to standard of care, on the progression of kidney…
Bayer HealthCare Pharmaceuticals Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.